{
  "authors": [
    {
      "author": "Lin-Peng Zheng"
    },
    {
      "author": "Li-Ying Chen"
    },
    {
      "author": "Xing-Yun Liao"
    },
    {
      "author": "Zi-Han Xu"
    },
    {
      "author": "Zheng-Tang Chen"
    },
    {
      "author": "Jian-Guo Sun"
    }
  ],
  "doi": "10.1186/s12885-018-4991-4",
  "publication_date": "2018-11-08",
  "id": "EN112944",
  "url": "https://pubmed.ncbi.nlm.nih.gov/30400855",
  "source": "BMC cancer",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy. The patient was initiated on osimertinib treatment with T790 M mutation detected (14.4%), but disease progressed 2 months later."
}